Lucence Diagnostics

29/05/2025

Excited that our ctRNA and ctDNA liquid biopsy study has been selected as a Top 10 lung cancer study at by OncoAlert

Join the oral presentation at 8:00–9:30 AM CDT on June 2, 2025 https://lnkd.in/ghbWfKNM

The Abstracts in 🫁
These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago 🇺🇸

⭐ Abs 8506: HERTHENA-LUNG02: PATRITUMAB DERUXTECAN IN RESISTANT EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER AFTER A THIRD-GENERATION EGFR TKI

⭐Abs 8006: IMFORTE: LURBINECTEDIN + ATEZOLIZUMAB AS FIRST-LINE (1L) MAINTENANCE TREATMENT IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER

⭐Abs 8512:TELISOTUZUMAB ADIZUTECAN (ABBV-400; TEMAB-A), A C-MET PROTEIN-TARGETING ADC, IN ADVANCED EGFR-MUTATED NON-SQUAMOUS (NSQ)

⭐LBA 8000: OVERALL SURVIVAL WITH NEOADJUVANT NIVOLUMAB (NIVO) + CHEMOTHERAPY (CHEMO) IN PATIENTS WITH RESECTABLE NSCLC IN CHECKMATE 816.

⭐LBA 8008: TARLATAMABVERSUS CHEMOTHERAPY AS SECOND-LINE (2L) TREATMENT FOR SMALL CELL LUNG CANCER (SCLC): PRIMARY ANALYSIS OF PH3 DELLPHI-304

⭐Abs 8001: NEOADJUVANT OSIMERTINIB ≤ CHEMOTHERAPY VS CT ALONE IN RESECTABLE EPIDERMAL GROWTH FACTOR RECEPTOR-MUTATED (EGFRM) NSCLC: NEOADAURA

⭐Abs 8015: ALECTINIB AS NEOADJUVANT TREATMENT IN POTENTIALLY RESECTABLE STAGE III ALK-POSITIVE NSCLC: FINAL ANALYSIS OF ALNEO

⭐Abs 8009: AEGEAN: ASSOCIATION OF POST-SURGICAL MRD STATUS W/ NEOADJUVANT CTDNA DYNAMICS, GENOMIC MUTATIONS / CLINICAL OUTCOMES IN RESECTABLE NSCLC

⭐Abs 8501: TROPION-LUNGO2: DATOPOTAMAB DERUXTECAN PLUS PEMBROLIZUMAB WITH OR WITHOUT PLATINUM CHEMOTHERAPY AS 1L FOR ADVANCED NSCLC

⭐Abs 8016: EFFICACY AND SAFETY OF NIVOLUMAB PLUS IPILIMUMAB FOR PRE-TREATED TYPE B3 THYMOMA AND THYMIC CARCINOMA: RESULTS FROM THE EORTC-ETOP NIVOTHYM

⭐Abs 3016: CLINICAL UTILITY OF CIRCULATING TUMOR RNA IN A COMBINED CIRCULATING TUMOR DNA & CTRNA NEXT-GENERATION SEQUENCING PAN-CANCER LIQUID BIOPSY ASSAY

Leads:
Senior Faculty:

23/05/2025

Join Lucence at as we present new data on our combined ctDNA and ctRNA liquid biopsy assay for cancer detection and monitoring!

🧬 Rapid Oral Presentation
Abstract #3016
Title: Clinical utility of circulating tumor RNA (ctRNA) in a combined circulating tumor DNA (ctDNA) and ctRNA next-generation sequencing (NGS) pan-cancer liquid biopsy assay
https://lnkd.in/ghbWfKNM
Presenter: Dr Daniel Chan
When: June 2, 8:00–9:30 AM CDT
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

📌 Poster Presentation
Abstract #3062
Title: Clinical outcomes of a prospective multicenter study evaluating a combined circulating tumor DNA (ctDNA) and RNA (ctRNA) liquid biopsy assay in metastatic non-small cell lung cancer (NSCLC)
https://lnkd.in/gDhiWGc9
Presenter: Prof GILBERTO de lima LOPES Junior
When: June 2, 1:30–4:30 PM CDT (Poster Board #377)
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Contact us at asco25@lucence.com to meet or for collaboration!

26/02/2025

Cancer is a global challenge, with close to 1 million deaths reported in India annually.

We’re glad to announce a collaboration with Agilus Diagnostics to contribute to India's cancer care.

For the first time, Indian cancer patients and physicians can now access LiquidHALLMARK® ctDNA and ctRNA to better personalize cancer treatment.

LiquidHALLMARK® is the only such test fully covered by US Medicare.

Together, we can do better!

Learn more: https://lnkd.in/d-YwBp5C

11/01/2025

We are honored to collaborate with Mayo Clinic Laboratories to expand access to advanced cancer diagnostics.

Together, we're delivering actionable genomic insights to support precision medicine and drive better outcomes worldwide!

Mayo Clinic Laboratories and Lucence are expanding access to advanced cancer testing worldwide with LiquidHALLMARK®, a next-generation liquid biopsy that provides actionable genomic insights. This collaboration empowers physicians to deliver personalized care and improve patient outcomes.

03/01/2025

We're glad to share today that the LiquidHallmark ctDNA/ctRNA liquid biopsy test has been granted Medicare coverage through a decision by the Molecular Diagnostic Service (MolDx) program.

This coverage decision means more cancer patients can access ctDNA/ctRNA testing, to identify more biomarkers for FDA-approved treatment options.

So much thanks to the support of our physicians, patients and partners that enabled us to achieve this milestone for US and international cancer patients!

Enterprise Singapore, SGInnovate, Agency for Science, Technology and Research (A*STAR)

https://www.lucence.com/lucencenews/lucence-secures-moldx-approval-for-liquidhallmark-ctdna-and-ctrna-liquid-biopsy-test-to-advance-non-invasive-cancer-diagnostics/

28/11/2024

Join Lucence at ESMO Asia 2024 in Singapore to learn more about multi-cancer screening!

Our CEO, Min-Han Tan will be speaking at a session on how technology enables Multi-Cancer Early Detection (MCED) liquid biopsies.

When: Saturday, 7 December 2024, 2:30 PM – 4:00 PM
Where: Suntec City, Room 324

Do join us to hear how MCED is shaping the future of healthcare!

20/11/2024

We’re thrilled to share that Lucence presented at the UBS Disruptive Technology CEO Summit 2024 in Hong Kong today!

Our CEO, Dr Tan Min-Han spoke on "Transforming Health: Multi-Cancer Screening in Blood", highlighting our mission to advance early cancer detection with LucenceINSIGHT™ for 50 cancers.

This summit brings together innovators, and at Lucence, we’re proud to contribute with our liquid biopsy technology for earlier, more accurate cancer detection.

A big thank you to UBS for this platform and to our Hong Kong partners, Gleneagles Hospital Hong Kong and Humansa, for your incredible support. Together, we’re building a future where earlier cancer detection saves more lives.

29/10/2024

We're glad to announce expanded access to our LiquidHALLMARK® ctDNA and ctRNA liquid biopsy test for Regence health plan members across the Pacific Northwest and Intermountain regions.

1 in 2 eligible lung cancer patients in the United States do not receive precision medicine treatments due to limitations in biomarker testing (Sadik et al, JCO PO, 2022).

This expanded coverage for means more US cancer patients can receive liquid biopsy testing that provides essential biomarker testing.

Participation includes Regence's commercial and Medicare Advantage plans where applicable, helping more patients access critical testing.

Very glad to advance personalized cancer care together with our partners!

PALO ALTO, CA, [28 October 2024] — Lucence, a precision oncology company, today announced that its LiquidHALLMARK® ctDNA and ctRNA liquid biopsy test will now be available to members of multiple Regence health plans across the Pacific Northwest and Intermountain regions. This expansion makes Liqu...

06/07/2024

Swift Sensitive Surveillance. Because Cure Matters.

Proud to announce our new HemeMark service upgrade - now immediately available. HemeMark is a comprehensive NGS test supporting decisions in blood cancers.

Key features:
🔸 72 genes (from 45 genes) and microsatellite instability for more useful actionable information guiding treatment decisions.
🔸 0.05% VAF (from 0.1% VAF) for even greater sensitivity, powered by our proprietary mirror barcodes.
🔸 2 weeks turnaround time
🔸 run in our CAP-accredited and CLIA-licensed laboratory.

100% concordance of mutations in paired blood and bone marrow has been shown at >0.5% VAF threshold using HemeMark, and 86% at >0.1% threshold (Lim B et al, AACR 2023)

Product brochure : https://lnkd.in/g6i7_zY9

For non-US physicians only.

29/04/2024

We're honored to win the $30,000 cash grand prize at the FedEx Small Business Grant Contest, selected among the Forbes Asia 100 to Watch companies.

Our CEO Min-Han Tan was very excited to share our vision for multi-cancer early detection blood testing - to save millions of lives around the world by screening and treating cancers earlier and better.

This powerful vision of accessible, non-invasive cancer testing would only be possible with partners like Fedex, thus allowing people to have the blood drawn from the comfort of their homes and then delivered to our central laboratories in Palo Alto and Singapore.

So much gratitude for the opportunity to share this vision at the Forbes Asia 100 to Watch Forum!

28/02/2024

We are thrilled to announce a significant milestone for Lucence: our LiquidHALLMARK® assay has now received comprehensive Medicare coverage for patients with all types of advanced solid tumors.

This is a pivotal moment in making liquid biopsy accessible to a broader range of cancer patients across the United States.

https://www.lucence.com/lucencenews/lucence-confirms-comprehensive-medicare-coverage-for-liquidhallmark-and-demonstrates-sensitive-detection-of-lung-cancer-biomarkers-in-prospective-study/

16/02/2024

We're honored to be a flagship company for the 20th anniversary of the US-Singapore Free Trade Agreement!

And so very glad our liquid biopsy technology can bridge better cancer care in both the USA and Singapore.